LON:RXB

Rex Bionics Share Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume314,960 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive RXB News and Ratings via Email

Sign-up to receive the latest news and ratings for Rex Bionics and its competitors with MarketBeat's FREE daily newsletter.


Rex Bionics logo

About Rex Bionics

Rex Bionics Plc is engaged in the research and development, manufacture and commercialization of robotic devices designed to provide physiotherapy to and improve the physical and psychological well-being of people with mobility impairment as a result of spinal cord injury or other neurological trauma, such as stroke or traumatic brain injury, or neurodegenerative disease. The Company develops and commercializes ReX, the hands-free, self-supporting, independently controlled robotic walking device for use in the rehabilitation of people with major mobility impairment. The Company offers two principal products: ReX and ReX P (Personal), which are targeted respectively at the professional neuro-rehabilitation clinic and personal homecare markets. The Company utilizes RAPPER II, which is an open label, single arm, non-randomized, non-comparative registry study of Robot-Assisted Physiotherapy Exercises with the REX Robot powered exercise system preventing unsupported patient ambulation.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Rex Bionics (LON:RXB) Frequently Asked Questions

What stocks does MarketBeat like better than Rex Bionics?

Wall Street analysts have given Rex Bionics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rex Bionics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Rex Bionics' key executives?

Rex Bionics' management team includes the following people:
  • David John Macfarlane, Chairman of the Board
  • Dominic Crispin Adam Simon, Chief Executive Officer, Director
  • Jeremy Laurence Curnock-Cook, Deputy Chairman of the Board
  • K. M. Robinson, Secretary
  • William L. Hunter M.D., Director
  • Joseph Anthony Cucolo, Non-Executive Director

Who are some of Rex Bionics' key competitors?

What is Rex Bionics' stock symbol?

Rex Bionics trades on the London Stock Exchange (LON) under the ticker symbol "RXB."

How do I buy shares of Rex Bionics?

Shares of RXB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

How many employees does Rex Bionics have?

Rex Bionics employs 147,000 workers across the globe.

What is Rex Bionics' official website?

The official website for Rex Bionics is www.rexbionicsuk.com.

Where are Rex Bionics' headquarters?

How can I contact Rex Bionics?

Rex Bionics' mailing address is 4th Fl, 1-3 Pemberton Row, LONDON, EC4A 3BG, United Kingdom. The company can be reached via phone at 14089961010.


This page was last updated on 9/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.